[1]
Song X,Zhao Z,Barber B,Farr AM,Ivanov B,Novich M, Overall survival in patients with metastatic melanoma. Current medical research and opinion. 2015 May;
[PubMed PMID: 25708472]
Level 3 (low-level) evidence
[2]
Matthews NH,Li WQ,Qureshi AA,Weinstock MA,Cho E,Ward WH,Farma JM, Epidemiology of Melanoma Cutaneous Melanoma: Etiology and Therapy. 2017 Dec 21;
[PubMed PMID: 29461782]
[3]
Wong VK, Lubner MG, Menias CO, Mellnick VM, Kennedy TA, Bhalla S, Pickhardt PJ. Clinical and Imaging Features of Noncutaneous Melanoma. AJR. American journal of roentgenology. 2017 May:208(5):942-959. doi: 10.2214/AJR.16.16800. Epub 2017 Mar 16
[PubMed PMID: 28301211]
[4]
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. The New England journal of medicine. 2017 Jun 8:376(23):2211-2222. doi: 10.1056/NEJMoa1613210. Epub
[PubMed PMID: 28591523]
[5]
MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. The New England journal of medicine. 2003 Feb 6:348(6):567-8
[PubMed PMID: 12571271]
[6]
Turner N, Ware O, Bosenberg M. Genetics of metastasis: melanoma and other cancers. Clinical & experimental metastasis. 2018 Aug:35(5-6):379-391. doi: 10.1007/s10585-018-9893-y. Epub 2018 May 2
[PubMed PMID: 29722002]
[7]
Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment cell & melanoma research. 2019 May:32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19
[PubMed PMID: 30712316]
[8]
Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 2019 May:9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20
[PubMed PMID: 30787016]
[9]
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of pathology & laboratory medicine. 2020 Apr:144(4):500-522. doi: 10.5858/arpa.2019-0561-RA. Epub 2020 Feb 14
[PubMed PMID: 32057276]
[10]
Friedman RJ, Rigel DS, Kopf AW, Lieblich L, Lew R, Harris MN, Roses DF, Gumport SL, Ragaz A, Waldo E, Levine J, Levenstein M, Koenig R, Bart RS, Trau H. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Archives of dermatology. 1983 Jun:119(6):455-62
[PubMed PMID: 6859885]
[11]
Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017 Dec 1:8(62):106132-106142. doi: 10.18632/oncotarget.22190. Epub 2017 Oct 31
[PubMed PMID: 29285320]
[12]
Maio M. Melanoma as a model tumour for immuno-oncology. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Sep:23 Suppl 8():viii10-4. doi: 10.1093/annonc/mds257. Epub
[PubMed PMID: 22918922]
[13]
Motofei IG. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches. Current treatment options in oncology. 2019 May 6:20(6):45. doi: 10.1007/s11864-019-0643-4. Epub 2019 May 6
[PubMed PMID: 31056729]
[14]
Motofei IG. Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches. Melanoma research. 2019 Jun:29(3):231-236. doi: 10.1097/CMR.0000000000000573. Epub
[PubMed PMID: 30615013]
[15]
Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017 Jun 1:123(S11):2143-2153. doi: 10.1002/cncr.30444. Epub
[PubMed PMID: 28543699]
[16]
Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Bénard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Human molecular genetics. 1998 Feb:7(2):209-16
[PubMed PMID: 9425228]
[17]
Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. Journal of medical genetics. 2013 Apr:50(4):264-70. doi: 10.1136/jmedgenet-2012-101455. Epub 2013 Feb 5
[PubMed PMID: 23384855]
[18]
Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature genetics. 1996 Jan:12(1):97-9
[PubMed PMID: 8528263]
[19]
Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature genetics. 1994 Sep:8(1):23-6
[PubMed PMID: 7987388]
[20]
Prota G, d'Ischia M, Mascagna D. Melanogenesis as a targeting strategy against metastatic melanoma: a reassessment. Melanoma research. 1994 Dec:4(6):351-8
[PubMed PMID: 7703714]
[21]
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo (Athens, Greece). 2014 Nov-Dec:28(6):1005-11
[PubMed PMID: 25398793]
[22]
Gandini S, Autier P, Boniol M. Reviews on sun exposure and artificial light and melanoma. Progress in biophysics and molecular biology. 2011 Dec:107(3):362-6. doi: 10.1016/j.pbiomolbio.2011.09.011. Epub 2011 Sep 19
[PubMed PMID: 21958910]
[23]
Vosmík F. [Malignant melanoma of the skin. Epidemiology, risk factors, clinical diagnosis]. Casopis lekaru ceskych. 1996 Jul 26:135(13):405-8
[PubMed PMID: 8925536]
[24]
Lejeune FJ. Epidemiology and etiology of malignant melanoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1986:40(3):91-9
[PubMed PMID: 3527290]
[25]
O'Neill CH, Scoggins CR. Melanoma. Journal of surgical oncology. 2019 Oct:120(5):873-881. doi: 10.1002/jso.25604. Epub 2019 Jun 27
[PubMed PMID: 31246291]
[26]
Uhara H. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. International journal of clinical oncology. 2019 Dec:24(12):1508-1514. doi: 10.1007/s10147-018-1246-y. Epub 2018 Feb 22
[PubMed PMID: 29470725]
Level 3 (low-level) evidence
[27]
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. The New England journal of medicine. 2005 Nov 17:353(20):2135-47
[PubMed PMID: 16291983]
[28]
Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma research. 2006 Aug:16(4):267-73
[PubMed PMID: 16845322]
[29]
Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, Kopf AW, Polsky D. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004 Dec 8:292(22):2771-6
[PubMed PMID: 15585738]
[30]
Daniel Jensen J, Elewski BE. The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations. The Journal of clinical and aesthetic dermatology. 2015 Feb:8(2):15
[PubMed PMID: 25741397]
[31]
Holmes GA, Vassantachart JM, Limone BA, Zumwalt M, Hirokane J, Jacob SE. Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. 2018 May:35(Suppl 4):S39-S45
[PubMed PMID: 30766399]
[32]
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017 Nov:67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13
[PubMed PMID: 29028110]
[33]
Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers. 2010 Dec 30:3(1):126-63. doi: 10.3390/cancers3010126. Epub 2010 Dec 30
[PubMed PMID: 24212610]
[34]
Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Apr 1:21(7):1326-31
[PubMed PMID: 12663722]
[35]
Bunnell AM, Nedrud SM, Fernandes RP. Classification and Staging of Melanoma in the Head and Neck. Oral and maxillofacial surgery clinics of North America. 2022 May:34(2):221-234. doi: 10.1016/j.coms.2021.12.001. Epub
[PubMed PMID: 35491079]
[36]
Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British journal of cancer. 2006 Sep 4:95(5):581-6
[PubMed PMID: 16880785]
Level 1 (high-level) evidence
[37]
Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochemical pharmacology. 2014 Feb 1:87(3):381-9. doi: 10.1016/j.bcp.2013.11.013. Epub 2013 Nov 28
[PubMed PMID: 24291778]
[38]
Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA oncology. 2015 Jun:1(3):380-6. doi: 10.1001/jamaoncol.2015.0565. Epub
[PubMed PMID: 26181188]
Level 3 (low-level) evidence
[39]
Teh JL, Chen S. Glutamatergic signaling in cellular transformation. Pigment cell & melanoma research. 2012 May:25(3):331-42. doi: 10.1111/j.1755-148X.2012.00983.x. Epub 2012 Feb 20
[PubMed PMID: 22273393]
[40]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016 Jan-Feb:66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7
[PubMed PMID: 26742998]
[41]
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011 Jun 30:364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5
[PubMed PMID: 21639808]
[42]
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012 Oct:3(10):1068-111
[PubMed PMID: 23085539]
[43]
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer discovery. 2020 Jan:10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28
[PubMed PMID: 31658955]
[44]
Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, Marais R. A mouse model of melanoma driven by oncogenic KRAS. Cancer research. 2010 Jul 1:70(13):5549-57. doi: 10.1158/0008-5472.CAN-09-4254. Epub 2010 Jun 1
[PubMed PMID: 20516123]
[45]
Haanen JB. Immunotherapy of melanoma. EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]. 2013 Sep:11(2):97-105. doi: 10.1016/j.ejcsup.2013.07.013. Epub
[PubMed PMID: 26217118]
[46]
Green J, Ariyan C. Update on immunotherapy in melanoma. Surgical oncology clinics of North America. 2015 Apr:24(2):337-46. doi: 10.1016/j.soc.2014.12.010. Epub 2015 Jan 22
[PubMed PMID: 25769716]
[47]
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (New York, N.Y.). 2018 Mar 23:359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22
[PubMed PMID: 29567705]
[48]
Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. International journal of molecular sciences. 2020 Nov 26:21(23):. doi: 10.3390/ijms21238984. Epub 2020 Nov 26
[PubMed PMID: 33256089]
[49]
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (New York, N.Y.). 2001 Jan 12:291(5502):319-22
[PubMed PMID: 11209085]
[50]
Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proceedings of the National Academy of Sciences of the United States of America. 2016 Apr 26:113(17):E2383-92. doi: 10.1073/pnas.1603892113. Epub 2016 Apr 11
[PubMed PMID: 27071130]
[51]
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (New York, N.Y.). 1995 Nov 10:270(5238):985-8
[PubMed PMID: 7481803]
[52]
Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer immunology research. 2016 Mar:4(3):194-203. doi: 10.1158/2326-6066.CIR-15-0210. Epub 2016 Jan 19
[PubMed PMID: 26787823]
[53]
Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. Journal of immunology (Baltimore, Md. : 1950). 2002 May 1:168(9):4420-9
[PubMed PMID: 11970985]
[54]
Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual review of immunology. 2001:19():565-94
[PubMed PMID: 11244047]
[55]
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thüsen JV, Grünhagen DJ, Verhoef C, van Hall T, Aerts JG. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer cell. 2020 Nov 9:38(5):685-700.e8. doi: 10.1016/j.ccell.2020.09.001. Epub 2020 Oct 1
[PubMed PMID: 33007259]
[56]
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010 Aug 19:363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5
[PubMed PMID: 20525992]
[57]
Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. European journal of cancer (Oxford, England : 1990). 2015 Nov:51(17):2689-97. doi: 10.1016/j.ejca.2015.08.012. Epub 2015 Sep 10
[PubMed PMID: 26364516]
[58]
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jun 10:33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9
[PubMed PMID: 25667295]
[59]
Kudchadkar RR, Michielin O, van Akkooi ACJ. Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2018 May 23:38():759-762. doi: 10.1200/EDBK_200241. Epub
[PubMed PMID: 30231370]
[60]
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine. 2011 Jun 30:364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5
[PubMed PMID: 21639810]
[61]
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA, CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The New England journal of medicine. 2017 Nov 9:377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10
[PubMed PMID: 28891423]
[62]
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. The New England journal of medicine. 2018 May 10:378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15
[PubMed PMID: 29658430]
[63]
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 2015 Aug 1:386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4. Epub 2015 May 31
[PubMed PMID: 26037941]
Level 1 (high-level) evidence
[64]
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England journal of medicine. 2015 Jan 1:372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16
[PubMed PMID: 25399551]
[65]
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. The New England journal of medicine. 2014 Nov 13:371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29
[PubMed PMID: 25265494]
[66]
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2016 Sep:17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30
[PubMed PMID: 27480103]
Level 1 (high-level) evidence
[67]
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jul 1:28(7):1631-1639. doi: 10.1093/annonc/mdx176. Epub
[PubMed PMID: 28475671]
[68]
Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 1:28(5):1137-1144. doi: 10.1093/annonc/mdx040. Epub
[PubMed PMID: 28444112]
[69]
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology. 2018 May:19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21
[PubMed PMID: 29573941]
Level 1 (high-level) evidence
[70]
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2018 Oct:19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12
[PubMed PMID: 30219628]
Level 1 (high-level) evidence
[71]
Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). International journal of radiation oncology, biology, physics. 2016 Jun 1:95(2):632-46. doi: 10.1016/j.ijrobp.2016.01.038. Epub
[PubMed PMID: 27131079]
Level 3 (low-level) evidence
[72]
Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2019 Apr 1:17(4):367-402. doi: 10.6004/jnccn.2019.0018. Epub
[PubMed PMID: 30959471]
Level 1 (high-level) evidence
[73]
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023 Jan:73(1):17-48. doi: 10.3322/caac.21763. Epub
[PubMed PMID: 36633525]